chr3-38726877-G-A
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP4_StrongBP6BS2
The NM_006514.4(SCN10A):c.2816C>T(p.Pro939Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000182 in 1,614,096 control chromosomes in the GnomAD database, including 2 homozygotes. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_006514.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SCN10A | ENST00000449082.3 | c.2816C>T | p.Pro939Leu | missense_variant | 17/28 | 1 | NM_006514.4 | ENSP00000390600.2 | ||
SCN10A | ENST00000643924.1 | c.2816C>T | p.Pro939Leu | missense_variant | 16/27 | ENSP00000495595.1 | ||||
SCN10A | ENST00000655275.1 | c.2843C>T | p.Pro948Leu | missense_variant | 17/28 | ENSP00000499510.1 |
Frequencies
GnomAD3 genomes AF: 0.000138 AC: 21AN: 152206Hom.: 1 Cov.: 33
GnomAD3 exomes AF: 0.000267 AC: 67AN: 251328Hom.: 0 AF XY: 0.000287 AC XY: 39AN XY: 135834
GnomAD4 exome AF: 0.000186 AC: 272AN: 1461890Hom.: 1 Cov.: 33 AF XY: 0.000227 AC XY: 165AN XY: 727248
GnomAD4 genome AF: 0.000138 AC: 21AN: 152206Hom.: 1 Cov.: 33 AF XY: 0.000121 AC XY: 9AN XY: 74364
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, no assertion criteria provided | provider interpretation | Stanford Center for Inherited Cardiovascular Disease, Stanford University | Mar 09, 2017 | p.Pro939Leu (P939L; c.2816C>T) in exon 16 of the SCN10A gene (NM_006514.3) Chromosome position 3:38768368 G / A We classify this as a variant of uncertain significance (VUS), concluding that there is not sufficient evidence for its pathogenicity to warrant using it for diagnosis or predictive genetic testing. It has not been reported in another person with our patient’s phenotype as of 4/12/2017, it is in a gene of uncertain significance, and it is found in the general population at an appreciable frequency. This variant has been reported in one individual affected with painful peripheral neuropathy (Faber et al. 2012, PMID: 23115331). However, it did not meet the authors’ criteria to move on to functional in vitro studies (criteria: <1% allelic frequency in public databases, segregation in affected individuals when available to test, alteration of a conserved residue in a transmembrane segment or a previously identified functional motif that regulates channel current). This is a conservative amino acid change, resulting in the replacement of a nonpolar Proline with a nonpolar Leucine. Proline at this location is poorly conserved across vertebrate species, and is frequently replaced by Alanine, Serine, or Arginine. Leucine is the default amino acid in at least one mammalian species. There are no Likely Pathogenic or Pathogenic missense variants listed in ClinVar within 10 amino acids to either side as of 4/11/2017. According to the Invitae report, algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies. In total the variant has been seen in at least 69 out of >140,000 individuals from publicly available population datasets. Specifically, it was reported in 16/5,069 Ashkenazi Jewish, 12/9,434 East Asian, 8/15,391 South Asian, 27/63,271 non-Finnish European, 4/17,209 Latino, and 2/3,232 “Other†ancestry individuals in the gnomAD database, which includes variant calls on ~140,000 individuals of European, African, Latino, South Asian, Ashkenazi, and East Asian descent. Out patient’s ancestry is Latino. The overall allele frequency in gnomAD is 0.02%, and the highest allele frequency is 0.16% in Ashkenazi Jews. This would translate into 1 in 317 people with Ashkenazi Jewish ancestry having the variant (which is likely too common to be a cause of Brugada syndrome). The phenotype of those individuals is not publicly available. The dataset is comprised of multiple cohorts, some of which were recruited from the general population, others were enriched for common cardiovascular disease. The curators made an effort to exclude individuals with severe pediatric diseases. - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Jan 03, 2019 | The P939L variant in the SCN10A gene has been reported previously as heterozygous in an individual with painful neuropathy, however it is unclear if this patient was compound heterozygous for another variant (Faber et al., 2012). The P939L variant is observed in 69/277034 (0.025%) alleles in large population cohorts (Lek et al., 2016). The P939L variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. In-silico analyses, including protein predictors and evolutionary conservation, support that this variant does not alter protein structure/function. We interpret P939L as a variant of uncertain significance. - |
Brugada syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 08, 2023 | - - |
Cardiovascular phenotype Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 02, 2020 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at